We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+13.44%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$329M
AUM Growth
+$94M
(+40%)
Cap. Flow
+$80.7M
Cap. Flow
% of AUM
24.51%
Top 10 Holdings %
Top 10 Hldgs %
27.28%
Holding
112
New
38
Increased
35
Reduced
8
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$7.49M |
| 2 |
KTWO
K2M Group Holdings, Inc
KTWO
|
+$6.3M |
| 3 |
Stryker
SYK
|
+$5.17M |
| 4 |
Medpace
MEDP
|
+$4.63M |
| 5 |
Abbott
ABT
|
+$4.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$6.94M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$6.34M |
| 3 |
Universal Health Services
UHS
|
+$5.36M |
| 4 |
McKesson
MCK
|
+$5.13M |
| 5 |
ACH
Accendra Health
ACH
|
+$4.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.31% |
| 2 | Financials | 2.43% |
| 3 | Industrials | 2.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
HCA Healthcare
HCA
$87.2B
| $10.6M | 3.22% |
+140,000
| New | +$10.7M |
|
|
2
Stryker
SYK
$125B
| $9.82M | 2.98% |
84,333
+44,333
| +111% | +$5.17M |
|
|
AGN
3
PUT
DELISTED
Allergan plc
AGN
| $9.79M | 2.97% |
42,500
| – | – |
|
4
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.04B
| $9.13M | 2.77% |
150,000
+25,000
| +20% | +$1.52M |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $9.12M | 2.77% |
365,000
+165,000
| +83% | +$3.85M |
|
|
6
CALL
Stryker
SYK
$125B
| $8.73M | 2.65% |
+75,000
| New | +$8.74M |
|
|
7
Abbott
ABT
$183B
| $8.67M | 2.63% |
205,000
+105,000
| +105% | +$4.5M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
| $8.13M | 2.47% |
66,375
+21,705
| +49% | +$2.79M |
|
|
AET
9
DELISTED
Aetna Inc
AET
| $8M | 2.43% |
69,333
-8,167
| -11% | -$957K |
|
|
BCR
10
PUT
DELISTED
CR Bard Inc.
BCR
| $7.85M | 2.38% |
+35,000
| New | +$7.88M |
|
11
Baxter International
BAX
$13.5B
| $7.62M | 2.31% |
160,000
+12,695
| +9% | +$599K |
|
12
Eli Lilly
LLY
$1.02T
| $7.49M | 2.28% |
93,375
+37,375
| +67% | +$2.99M |
|
|
13
Novartis
NVS
$297B
| $7.27M | 2.21% |
+102,812
| New | +$7.49M |
|
14
Amgen
AMGN
$208B
| $7.25M | 2.2% |
43,460
+16,210
| +59% | +$2.74M |
|
|
SHPG
15
DELISTED
Shire pic
SHPG
| $7.25M | 2.2% |
37,391
+7,391
| +25% | +$1.44M |
|
16
Centene
CNC
$30.7B
| $7.13M | 2.17% |
212,958
+2,958
| +1% | +$103K |
|
|
ATHN
17
DELISTED
Athenahealth, Inc.
ATHN
| $6.94M | 2.11% |
55,000
+25,000
| +83% | +$3.18M |
|
|
EVHC
18
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $6.84M | 2.08% |
102,553
+32,413
| +46% | +$2.23M |
|
|
EVHC
19
PUT
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $6.68M | 2.03% |
+100,200
| New | +$6.9M |
|
|
KTWO
20
DELISTED
K2M Group Holdings, Inc
KTWO
| $6.67M | 2.03% |
+375,223
| New | +$6.3M |
|
|
21
CALL
Eli Lilly
LLY
$1.02T
| $6.54M | 1.99% |
+81,500
| New | +$6.52M |
|
22
GSK
GSK
$104B
| $6.49M | 1.97% |
120,286
+40,986
| +52% | +$2.25M |
|
23
Zimmer Biomet
ZBH
$18.2B
| $5.29M | 1.61% |
41,872
-14,778
| -26% | -$1.83M |
|
|
SIEN
24
DELISTED
Sientra, Inc.
SIEN
| $4.97M | 1.51% |
55,266
+20,266
| +58% | +$1.57M |
|
25
Boston Scientific
BSX
$69.5B
| $4.76M | 1.45% |
200,000
+15,000
| +8% | +$358K |
|
Similar funds
GMP
BCA
ONGA
RC
DOFI
SRA
SR
TC
Pura Vida Investments's Q3 2016 Portfolio in Review
As of Q3 2016, Pura Vida Investments held 112 positions worth $329M, up 40% from $235M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pura Vida Investments deployed $80.7M of net new capital in Q3 2016, opening 38 new positions and adding to 35 existing holdings. Its largest new stake was Novartis: 102,812 shares worth $7.27M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Insulet, an estimated $2.8M trimmed.
- Pura Vida Investments's largest Q3 2016 buy was Novartis: 102,812 shares worth $7.27M.
- Pura Vida Investments added most to Stryker in Q3 2016, an estimated $5.17M increase.
- Pura Vida Investments's biggest Q3 2016 reduction was Insulet, cutting an estimated $2.8M.
- Pura Vida Investments fully exited Medtronic in Q3 2016, selling an estimated $6.94M.
- Pura Vida Investments's ten largest holdings make up 27% of its $329M portfolio in Q3 2016.
- Pura Vida Investments opened 38 new positions and closed 25 in Q3 2016.
- Pura Vida Investments's portfolio value rose 40% quarter-over-quarter to $329M.
Based on Pura Vida Investments's 13F filing for Q3 2016, filed 14 Nov 2016.